Phosphoproteomics-Based Modeling Defines the Regulatory Mechanism Underlying Aberrant EGFR Signaling

• Shinya Tasaki,

  Affiliations Medical Proteomics Laboratory, Institute of Medical Science, University of Tokyo, Tokyo, Japan, Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan

  ⨯
• Masao Nagasaki,

  Affiliation Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan

  ⨯
• Hiroko Kozuka-Hata,

  Affiliation Medical Proteomics Laboratory, Institute of Medical Science, University of Tokyo, Tokyo, Japan

  ⨯
• Kentaro Semba,

  Affiliation Department of Life Science and Medical Bio-Science, Waseda University, Tokyo, Japan

  ⨯
• Noriko Gotoh,

  Affiliation Division of Systems Biomedical Technology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

  ⨯
• Seisuke Hattori,

  Affiliations Division of Cellular Proteomics (BML), Institute of Medical Science, University of Tokyo, Tokyo, Japan, Department of Biochemistry, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan

  ⨯
• Jun-ichiro Inoue,

  Affiliations Medical Proteomics Laboratory, Institute of Medical Science, University of Tokyo, Tokyo, Japan, Department of Cancer Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

  ⨯
• Tadashi Yamamoto,

  Affiliation Department of Cancer Biology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

  ⨯
• Satoru Miyano,

  Affiliation Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan

  ⨯
• Sumio Sugano,

  Affiliation Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan

  ⨯
• Masaaki Oyama

  * E-mail: moyama@ims.u-tokyo.ac.jp

  Affiliation Medical Proteomics Laboratory, Institute of Medical Science, University of Tokyo, Tokyo, Japan

  ⨯